See the DrugPatentWatch profile for vevye
What Is the Vevye Concentration?
Vevye (cyclosporine ophthalmic solution) comes in a 0.1% concentration. This means each milliliter of the emulsion contains 1 mg of cyclosporine, the active ingredient used to treat the signs and symptoms of dry eye disease.[1]
How Is Vevye Administered?
Patients instill 1 drop into each affected eye twice daily, about 12 hours apart. The single-use preservative-free vials make it suitable for sensitive eyes.[1][2]
How Does Vevye Differ from Restasis?
Vevye uses a nanomicellar formulation for better tolerability and no stinging on instillation, unlike Restasis (also 0.05% cyclosporine but with a different emulsion). Vevye's higher 0.1% strength aims for faster symptom relief.[2][3]
Who Makes Vevye and What's the Pricing?
Harrow Inc. developed and markets Vevye, approved by the FDA in 2023. A 30-day supply (60 vials) costs around $850-$900 without insurance, though copay cards can reduce it to $40 for eligible patients.[4]
When Do Vevye Patents Expire?
Key U.S. patents for Vevye's formulation (e.g., US 11,154,453 for the nanomicellar tech) expire between 2037 and 2041. No generics are expected soon due to method-of-use and formulation protections.[5]
[1]: FDA Label - Vevye (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215785s000lbl.pdf)
[2]: Harrow Inc. Prescribing Information (https://www.vevye.com/)
[3]: Clinical Trials Data - ODYSSEY Study (https://www.harrow.com/vevye)
[4]: GoodRx Pricing (https://www.goodrx.com/vevye)
[5]: DrugPatentWatch.com - Vevye Patents (https://www.drugpatentwatch.com/p/tradename/VEVYE)